http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA05009095-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00 |
| filingDate | 2004-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7aa7bc3b588e4dadf01bbb72f2d2a462 |
| publicationDate | 2006-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-PA05009095-A |
| titleOfInvention | FINAL ENTERIC PARTICLES OF SUSTAINED RELEASE OF TAMSULOSIN OR ITS SALT AND METHOD OF MANUFACTURING THEMSELVES. |
| abstract | The present invention relates to fine enteric particles of sustained release of tamsulosin or its salt that may be contained in tablets that disintegrate in the oral cavity and a method of manufacturing them. With further details, the present invention relates to fine enteric particles of sustained release for tablets that disintegrate in the oral cavity, which comprise (1) tamsulosin or its salt and at least (2) an enterosoluble substance, and when necessary ( 3) contain a substance not soluble in water, and which has the following characteristics: 1) a particle diameter of approximately 5 to 250 µm, 2) when dissolution tests are carried out on the tablets that disintegrate into the oral cavity that these particles contain through the dissolution test methods mentioned in the Japanese Pharmacopoeia, a) the dissolution range of tamsulosin or its salt with a pH of 1.2 two hours after the start of the tests is 25% or less, b) the time in which 50% of tamsulosin or its salt is dissolved with a pH of 6.8 is 0.5 to 5 hours, and a method of manufacturing them. |
| priorityDate | 2003-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.